Galapagos Enters Into Oncology Target Discovery Collaboration with Janssen Pharmaceutica
MECHELEN, Belgium; 3 January 2008 - Galapagos NV (Euronext &
LSE: GLPG) announced today a new two-year target discovery
collaboration between Janssen Pharmaceutica and BioFocus DPI,
Galapagos' service division, in the field of oncology.
BioFocus DPI will apply Galapagos' proprietary adenoviral platform
to identify novel drug targets for the development of cancer
therapies.
The goal of the new collaboration will be to discover and validate
novel targets in the field of oncology. BioFocus DPI will
perform assay development, screening of the SilenceSelect® and
FLeXSelect® adenoviral libraries, and target validation.
Target discovery in cutting edge in vitro assays may provide novel
drug targets for cancer areas with an unmet medical need.
BioFocus DPI receives an upfront payment of €2.9
million. In total, BioFocus DPI may receive additional
research, acceptance, license and development fees of up to
€7.6 million should certain predetermined criteria be
achieved.
"This marks BioFocus DPI's first target discovery agreement in
oncology, as well as the largest target discovery agreement to date
for the service division," said Onno van de Stolpe, Chief Executive
Officer of Galapagos.
About BioFocus DPI
BioFocus DPI is the service division of Galapagos. It offers
a full suite of target-to-drug discovery products and services to
pharmaceutical and biotech companies, encompassing target discovery
and validation, screening and drug discovery through to delivery of
pre-clinical candidates. BioFocus DPI also provides
adenoviral reagents for rapid identification and validation of
novel drug targets, compound libraries for drug screening as well
as chemogenomics and ADMET database products to select targets and
compounds. More information about BioFocus DPI can be found
at www.biofocusdpi.com.
About Galapagos
Galapagos (Euronext Brussels, GLPG; Euronext Amsterdam, GLPGA;
London AiM: GLPG) is a drug discovery company with pre-clinical
programs in bone and joint diseases and cachexia. Galapagos
currently employs 460 people and operates facilities in seven
countries, with global headquarters in Mechelen, Belgium.
More information about Galapagos can be found at www.glpg.com.
CONTACT
Galapagos NV
Onno van de Stolpe, CEO
Tel: +31 6 2909 8028
ir@glpg.com
This release may contain forward-looking statements, including,
without limitation, statements containing the words "believes,"
"anticipates," "expects," "intends," "plans," "seeks," "estimates,"
"may," "will," "could," "stands to," and "continues," as well as
similar expressions. Such forward-looking statements may
involve known and unknown risks, uncertainties and other factors
which might cause the actual results, financial condition,
performance or achievements of Galapagos, or industry results, to
be materially different from any historic or future results,
financial conditions, performance or achievements expressed or
implied by such forward-looking statements. Given these
uncertainties, the reader is advised not to place any undue
reliance on such forward looking statements. These
forward-looking statements speak only as of the date of publication
of this document. Galapagos expressly disclaims any
obligation to update any such forward-looking statements in this
document to reflect any change in its expectations with regard
thereto or any change in events, conditions or circumstances on
which any such statement is based, unless required by law or
regulation.
Pharma Industry News Archive
2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec
